Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer

Launched by SHAO PENGFEI · Oct 27, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how artificial intelligence (AI) can help doctors diagnose and treat prostate cancer more accurately. The goal is to see if AI can analyze MRI scans and other pathology images to predict whether a patient has prostate cancer, how aggressive it might be, and what type it is. The study will also look at whether the AI can help understand the results of surgery for new patients based on previous cases.

To participate in this trial, individuals must be male and have symptoms suggestive of prostate cancer, such as a high PSA level or suspicious findings on an ultrasound or MRI. Participants will undergo an MRI scan, which the AI will analyze to help make a diagnosis. If prostate cancer is detected, they will have surgery to remove the prostate. This trial is not yet recruiting participants, and it is important to note that those with prior treatments for prostate cancer or serious health issues may not be eligible.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with suspected PCa (elevated PSA or suspicious positive lesions on ultrasound or MRI results);
• Exclusion Criteria:
• • Previous treatment of the prostate in any form, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy and immunotherapy;
• • Patients with any item missing from the baseline clinical and pathological information;
• • Patients with a history of other malignancies, serious comorbidities or other health problems;
• • Unable to provide/sign an informed consent form;
• • Patients who, in the judgement of the investigator, are deemed unfit to participate in this clinical trial;